Tag Archives: Research and Development
Publicly traded companies in the pharmaceutical distribution system must disclose annual financial information to the SEC. Those reports provide some of the most reliable public information about how funds flow through the distribution system.
June 13, 2017
The claim that “everyone gets a free ride off us,” pushed by pharmaceutical companies to the US public and policy makers, is simply not true. It has been made so often for so long that many hold it as an economic fact, even though no solid evidence is presented to back it up.
June 2, 2017
If US policy makers were to enact regulations that drive prices down significantly, many projects that now have positive expected returns would no longer be profitable. Current prices would be lower but so would the expected level of future innovation.
June 2, 2017
The central, intractable obstacle to long-term cost containment is the near impossibility of saying “no” to ever-more-expensive care that yields small marginal benefits.
April 26, 2017
This latest step in a global effort to develop an effective HIV vaccine builds on a legacy of failure, hubris, and reinvention. Each stage of this history has much to teach us about the development of preventive vaccines in general.
December 21, 2016
Recent commentaries express concern about the impact of our proposal that the federal government consider using an existing law to negotiate or compel lower drug prices. We believe that the impact on innovation in fact would be minimal, and the results for society highly positive.
July 28, 2016
Government Appropriation Of Breakthrough Drug Patent Rights Would Deter Biopharmaceutical R&D And Innovation
Section 1498 allows the government eminent domain-type powers to circumvent an inventor’s patent exclusivity rights in exchange for “reasonable and entire compensation.” While some argue this could be used to drive down drug prices, however this may cause adverse consequences for R&D incentives...
June 20, 2016
With the growing importance of pharmaceuticals, Anthem and Eli Lilly identified two areas that we believe must be addressed in order to unleash a new wave of innovative approaches to pharmaceutical pricing.
January 29, 2016
Welcome to “From the Archives,” a Health Affairs Blog series, where we take a timely topic and delve into the literature and history, from a Health Affairs angle, of course. Harvoni, Sovaldi, Repatha, Daraprim. Four drugs that have made news for how much they cost patients and insurers. But...
November 24, 2015
A new policy brief from Health Affairs and the Robert Wood Johnson Foundation describes the repercussions of antibiotic resistance: when drugs have declining, limited, or no effectiveness in combatting certain bacterial infections.
May 22, 2015